Faculty Collaboration Database

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease Nature Aging March 2026;6(3):626-635

Date

03/01/2026

DOI

10.1038/s43587-026-01084-4

Scopus ID

2-s2.0-105030609326 (requires institutional sign-in at Scopus site)   1 Citation

Author List

Werner MH, McGarry A, Meyer C, Mancino E, Klint C, Pellecchia J, Kieburtz K, Levine T, Bellaire B, Gibbons C, Freeman R, Ellenbogen A, Klos K, Ospina M, Hauser RA, Shannon K, Asaad H, Park A, McAllister P, Isaacson SH, LeDoux MS, Dhall R, Shpiner D, Charles P, Agarwal P, Peckham E, Mazzeo P, Davis M, Pahwa R, Brodsky M, Lew M, Purino L, Mantri S, Parashos S, Justiz W, Chachar M, Robottom B, Budman E, Blindauer K, Bellows S, Goudreau J, Steen S, Olanow CW

Author

Karen A. Blindauer MD Chief, Professor in the Neurology department at Medical College of Wisconsin